Bone marrow suppression induced by systemic radionuclides (153Sm) in metastatic breast cancer patients with bone metastases, its impact on subsequent chemotherapy
Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 10
Abstract
Introduction: Bone metastases are present in approximately 75 percent of breast cancer patients, therefore bones are the most frequent localization of metastases and the only site of metastatic spread in many patients. Treatment of bone metastases remains palliative. The commonly used treatment options include: radiotherapy, bisphosphonate therapy and systemic radionuclides. Purpose: The aim of this study was to assess the safety of systemic samarium (153Sm) in breast cancer patients with widespread bone metastases and the impact of bone marrow suppression induced by (153Sm) treatment on hematologic toxicity of concomitant or subsequent chemotherapy. Materials and methods: Data from ninety metastatic breast cancer patients with bone metastases treated in the Lower Silesia Oncology Centre, who in 2002-2004 received 153Sm in the Nuclear Medicine Department of the 4th Military Hospital was included in the analysis. Sixty nine (77 percent) patients had bone only disease, while in 26 (23 percent), presence of metastases to other organs was confirmed. Fifty four (60 percent) patients were treated with radiotherapy before systemic radionuclides. The majority (80/90 – 89%) of patients received concurrently bisphosphonates, all patients required analgetics. Results: The treatment with radionuclides was generally well tolerated with short-term asymptomatic bone marrow suppression. In 16 (18%) of patients (5 from the group with disease limited to bones and 11 from the group with metastatic spread to other organs) treated with 153Sm, chemotherapy was planned or initiated. In 10 (62.5%) patients chemotherapy was delayed for a mean period of 4–8 weeks, then dose intensity had to be reduced due to the prolonged reduction of bone marrow reserve. In 4 (25%) patients chemotherapy was planned but not initiated due to persistent bone marrow suppression, only 2 (12.5%) of patients received the treatment with a cytotoxic drug without delay or dose reduction. Conclusions: Results of this study indicate that in metastatic breast cancer patients, if the clinical benefit from chemotherapy is expected, a caution should be recommended in planning palliative treatment with 153Sm due to the potential delay of cytotoxic therapy, though pathogenesis of long-term bone marrow suppression is multifactorial and it is unlikely that systemic radionuclides play a key role in myelosuppression.
Authors and Affiliations
Aleksandra Łacko, Katarzyna Pająk, Andrzej Kołodziejczyk, Jacek Żebrowski, Agnieszka Garncarek, Emilia Filipczyk-Cisarż
Keywords
Related Articles
- EP ID EP112758
- DOI -
- Views 45
- Downloads 0
Powierzchowna hipertermia skojarzona z hipofrakcjonowaną radioterapią przerzutów czerniaka złośliwego do skóry i węzłów chłonnych
Cel pracy: Celem pracy jest ocena skuteczności skojarzonej powierzchownej hipertermii z hipofrakcjonowaną radioterapią w leczeniu przerzutów czerniaka złośliwego do skóry i powierzchownych węzłów chłonnych. Materia...
Treatment of advanced invasive Thymomas in experience of Oncology Department at Regional Centre of Lung Diseases in Poznań and Department of Thoracic Surgery, Poznań University of Medical Sciences
Introduction: Thymoma is a rare neoplasm, deriving from epithelial tissue of Thymus. ADOC, PAC, PE and VIP are most frequently used combintions. Materials and method: Retrospective analysis including 13 patients treated...
Przerzuty do ośrodkowego układu nerwowego u chorych na rozsianego raka piersi leczonych trastuzumabem
Amplifikacja genu HER2 i/lub nadekspresja receptora HER2 występuje w 20–30 proc. inwazyjnych raków piersi i w 60 proc. raków śródprzewodowych. U chorych na inwazyjnego raka piersi zaburzenia genu HER2 związane są z bar...
A comparison of NMR scan to transrectal ultrasound - measured prostate volume in untreated prostate cancer
Purpose: Prostate cancer is one of the most common malignancies in men in developed European countries. Disease confined to the prostate gland can be definitively treated with radical radiation therapy. There are some...
Wyniki leczenia chorych na złośliwego międzybłoniaka opłucnej w materiale Centrum Onkologii w Krakowie
Celem pracy jest przedstawienie wyników leczenia chorych na złośliwego międzybłoniaka opłucnej w Centrum Onkologii w Krakowie. Materiał: W latach 1965–2003 w Centrum Onkologii w Krakowie leczono 63 chorych z powodu złoś...